Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000619002 | SCV000737719 | likely benign | Cardiovascular phenotype | 2023-07-18 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Athena Diagnostics | RCV000712060 | SCV000842474 | uncertain significance | not provided | 2021-04-07 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001370775 | SCV001567308 | uncertain significance | Spinocerebellar ataxia type 19/22 | 2023-08-28 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 600 of the KCND3 protein (p.Gly600Arg). This variant is present in population databases (rs149344567, gnomAD 0.01%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with clinical features of Brugada syndrome (PMID: 21349352, 22457051). ClinVar contains an entry for this variant (Variation ID: 192254). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects KCND3 function (PMID: 21349352, 22457051, 26016905). |
Gene |
RCV000712060 | SCV001812577 | uncertain significance | not provided | 2024-06-12 | criteria provided, single submitter | clinical testing | Reported in at least one individual with Brugada syndrome and sudden unexplained death (PMID: 22457051); At the protein level, in silico analysis indicates that this missense variant does not alter protein structure/function; At the mRNA level, in silico analysis is inconclusive as to whether the variant alters gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown.; Published functional studies suggest a damaging effect as this variant significantly increased peak current density and slowed transient outward current inactivation (PMID: 22457051); This variant is associated with the following publications: (PMID: 22840528, 29053796, 30662450, 22457051) |
Ai |
RCV000712060 | SCV002503338 | uncertain significance | not provided | 2021-05-16 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002505242 | SCV002815249 | uncertain significance | Spinocerebellar ataxia type 19/22; Brugada syndrome 9 | 2021-10-30 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000172843 | SCV000223809 | pathogenic | Brugada syndrome 9 | 2012-06-01 | no assertion criteria provided | literature only |